Insights into the management of penile squamous cell carcinoma: from conventional approaches to emerging novel therapies

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012;48(4):456–464. doi: 10.1016/j.ejca.2011.10.031
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi: 10.1002/ijc.33588
   Web of Science ®Google Scholar
• Youssef I, Hoogland AI, Chahoud J, et al. Patient reported outcomes in advanced penile cancer. J Urol Oncol. 2022;9(40):412.e9–412.e13.
   Google Scholar
• Deng X, Liu Y, Zhan X, et al. Trends in incidence, mortality, and survival of penile cancer in the United States: a population-based study. Front Oncol. 2022;12:12. doi: 10.3389/fonc.2022.891623
   Web of Science ®Google Scholar
• Chakiryan NH, Dahmen A, Bandini M, et al. Patterns of recurrence following inguinal lymph node dissection for penile cancer: optimizing surveillance strategies. J Urol. 2021;206(4):960–969. doi: 10.1097/JU.0000000000001790
   PubMed Web of Science ®Google Scholar
• Zekan DS, Dahman A, Hajiran AJ, et al. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol. 2021;47(5):943–956. doi: 10.1590/s1677-5538.ibju.2020.0959
   PubMed Web of Science ®Google Scholar
• Chahoud J, Zacharias NM, Pham R, et al. Prognostic significance of p16 and its relationship with human papillomavirus status in patients with penile squamous cell carcinoma: results of 5 years follow-up. Cancers (Basel). 2022;14(24):14. doi: 10.3390/cancers14246024
   Web of Science ®Google Scholar
• Parza K, Mustasam A, Ionescu F, et al. The prognostic role of human papillomavirus and p16 status in penile squamous cell carcinoma–a systematic review. Cancers (Basel). 2023;15(14):3713. doi: 10.3390/cancers15143713
   PubMed Web of Science ®Google Scholar
• Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16 INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20(1):145–158. doi: 10.1016/S1470-2045(18)30682-X
   PubMed Web of Science ®Google Scholar
• Yu A, Chahoud J, Necchi A, et al. The evolving landscape of viral, Immune, and molecular biomarkers in penile cancer. Urol Clin N Am. 2023;50(1):145–150. doi: 10.1016/j.ucl.2022.09.013
   PubMedGoogle Scholar
• Chahoud J, Kohli M, Spiess PE. Management of advanced penile cancer. Mayo Clin Proc. 2021;96(3):720–732. doi: 10.1016/j.mayocp.2020.06.031
   PubMed Web of Science ®Google Scholar
• Ahmed ME, Falasiri S, Hajiran A, et al. Review the immune microenvironment in penile cancer and rationale for immunotherapy. J Clin Med. 2020;9(10):3334. doi: 10.3390/jcm9103334
   PubMed Web of Science ®Google Scholar
• Chahoud J, Pickering CR, Pettaway CA. Genetics and penile cancer: recent developments and implications. Curr Opin Urol. 2019;29(4):364–370. doi: 10.1097/MOU.0000000000000640
   PubMed Web of Science ®Google Scholar
• Chahoud J, Gleber-Netto FO, McCormick BZ, et al. Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma a C. Clin Cancer Res. 2021;27(9):2560–2570. doi: 10.1158/1078-0432.CCR-20-4004
   PubMed Web of Science ®Google Scholar
• Aydin AM, Chahoud J, Adashek JJ, et al. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020;17(10):555–570. doi: 10.1038/s41585-020-0359-z
   PubMed Web of Science ®Google Scholar
• Mannweiler S, Sygulla S, Winter E, et al. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J Am Acad Dermatol. 2013;69(1):73–81. doi: 10.1016/j.jaad.2012.12.973
   PubMed Web of Science ®Google Scholar
• Smola S. Immunopathogenesis of HPV-associated cancers and prospects for immunotherapy. Viruses. 2017;9(9):254. doi: 10.3390/v9090254
   PubMed Web of Science ®Google Scholar
• Xu Q, Wang C, Yuan X, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with head and neck squamous cell carcinoma. Transl Oncol. 2017;10(1):10. doi: 10.1016/j.tranon.2016.10.005
   PubMed Web of Science ®Google Scholar
• Huang T, Cheng X, Chahoud J, et al. Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun. 2020;11(1):11. doi: 10.1038/s41467-020-15980-9
   PubMed Web of Science ®Google Scholar
• Chadha J, Chahoud J, Spiess PE. An update on treatment of penile cancer. Ther Adv Med Oncol. 2022;14:175883592211272. doi: 10.1177/17588359221127254
   Web of Science ®Google Scholar
• Chahoud J, Pham R, Sonpavde G. Innovative systemic therapies for penile cancer. Curr Opin Urol. 2022;32(1):8–16. doi: 10.1097/MOU.0000000000000941
   PubMed Web of Science ®Google Scholar
• Joshi VB, Spiess PE, Necchi A, et al. Immune-based therapies in penile cancer. Nat Rev Urol. 2022;19(8):457–474. doi: 10.1038/s41585-022-00617-x
   PubMed Web of Science ®Google Scholar
• Alkhouli MA, Bazargan S, Pilon-Thomas S, et al. Current state of cell therapies for genitourinary malignancies. Cancer J (United States). 2022;28(4):294–300. doi: 10.1097/PPO.0000000000000604
   Web of Science ®Google Scholar
• Joshi VB, Chadha J, Chahoud J. Penile cancer: updates in systemic therapy. Asian J Urol. 2022;9(4):374–388. doi: 10.1016/j.ajur.2022.03.006
   PubMed Web of Science ®Google Scholar
• Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology. 2010;76(2):S66–S73. doi: 10.1016/j.urology.2010.04.008
   PubMed Web of Science ®Google Scholar
• Djajadiningrat RS, Graafland NM, Van Werkhoven E, et al. Contemporary management of regional nodes in penile cancer—improvement of survival? J Urol. 2014;191(1):68–73. doi: 10.1016/j.juro.2013.07.088
   PubMed Web of Science ®Google Scholar
• Hakenberg OW, Compérat EM, Minhas S, et al. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–150. doi: 10.1016/j.eururo.2014.10.017
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–3857. doi: 10.1200/JCO.2010.29.5477
   PubMed Web of Science ®Google Scholar
• Azizi M, Aydin AM, Hajiran A, et al. Systematic review and meta-Analysis–is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma? J Urol. 2020;203(6):1147–1155. doi: 10.1097/JU.0000000000000746
   PubMedGoogle Scholar
• Chahoud J, Mustasam A, Rose KM, et al. 1310MO neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): an international, multicenter, real-world study. Ann Oncol. 2022;33:S1143. doi: 10.1016/j.annonc.2022.07.1443
   Google Scholar
• Di Lorenzo G, Buonerba C, Federico P, et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012;110(11b):110. doi: 10.1111/j.1464-410X.2012.11453.x
   Web of Science ®Google Scholar
• Sharma P, Djajadiningrat R, Zargar-Shoshtari K, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node–positive penile cancer after lymph node dissection: a multi-institutional study. J Urol Oncol. 2015;33(11):e496.17–e496.23. doi: 10.1016/j.urolonc.2015.05.008
   Web of Science ®Google Scholar
• Canter DJ, Nicholson S, Watkin N, et al. The international penile advanced cancer trial (InPACT): rationale and Current status. Eur Urol Focus. 2019;5(5):706–709. doi: 10.1016/j.euf.2019.05.010
   PubMedGoogle Scholar
• Heyns CF, Mendoza-Valds A, Pompeo ACL. Diagnosis and staging of penile cancer. Urology. 2010;76(2):S15–S23. doi: 10.1016/j.urology.2010.03.002
   PubMed Web of Science ®Google Scholar
• Pettaway CA, Pagliaro L, Theodore C, et al. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology. 2010;76(2):S58–S65. doi: 10.1016/j.urology.2010.03.082
   PubMed Web of Science ®Google Scholar
• Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109(10):2554–2559. doi: 10.1038/bjc.2013.620
   PubMed Web of Science ®Google Scholar
• Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest oncology group study. J Urol. 1999;161(6):1823–1825. doi: 10.1016/S0022-5347(05)68815-5
   PubMed Web of Science ®Google Scholar
• Wang J, Pettaway CA, Pagliaro LC. Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes. Urology. 2015;85(5):1104–1110. doi: 10.1016/j.urology.2014.12.049
   PubMedGoogle Scholar
• Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol [Internet]. 2018 Jul 11;62:29–39. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29990692
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018 Nov 10;363:k4226. doi: 10.1136/bmj.k4226
   PubMed Web of Science ®Google Scholar
• Labadie BW, Balar AV, Luke JJ. Immune checkpoint inhibitors for genitourinary cancers: treatment indications, investigational approaches and biomarkers. Cancers (Basel). 2021 Nov 14;13(21):5415. doi: 10.3390/cancers13215415
   PubMed Web of Science ®Google Scholar
• Stoehr R, Wendler O, Giedl J, et al. No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis. Pathobiology. 2019 Jan 17;86:145–151. doi: 10.1159/000495251
   PubMed Web of Science ®Google Scholar
• Jacob JM, Ferry EK, Gay LM, et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol. 2019;201(3):541–548. doi: 10.1016/j.juro.2018.09.056
   PubMed Web of Science ®Google Scholar
• FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors.
   Google Scholar
• NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines®) penile cancer. Available from: https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf.
   Google Scholar
• Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. [Internet]. 2022 May 28;29(5):3044–3060. doi: 10.3390/curroncol29050247
   PubMed Web of Science ®Google Scholar
• Franklin MR, Platero S, Saini KS, et al. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer 2022 Jan 14;10(1):e003231. doi: 10.1136/jitc-2021-003231
   PubMed Web of Science ®Google Scholar
• Safa H, Abu Rous F, Belani N, et al. Emerging biomarkers in immune oncology to Guide lung cancer management. Target Oncol. 2023 [ 2022 Dec 29];18(1):25–49. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36577876
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol [Internet]. 2012 Feb 24;6(2):140–146. doi: 10.1016/j.molonc.2012.01.010
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015 Feb 20;14(4):847–856. doi: 10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019 Oct 28;7(1):278. doi: 10.1186/s40425-019-0768-9
   PubMed Web of Science ®Google Scholar
• De Bacco MW, Carvalhal GF, B M, et al. PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region. Clin Genitourin Cancer [Internet]. 2020 Mar 07;18(3):e254–e259. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32139302.
   PubMed Web of Science ®Google Scholar
• Cocks M, Taheri D, Ball MW, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol [Internet]. 2016 Sep 25;59:55–61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27663086
   PubMed Web of Science ®Google Scholar
• Chu C, Yao K, Lu J, et al. Immunophenotypes based on the tumor immune microenvironment allow for unsupervised penile cancer patient stratification. Cancers (Basel) [Internet]. 2020 Jul 09;12(7):1796. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32635549.
   PubMed Web of Science ®Google Scholar
• Udager AM, Liu TY, Skala SL, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol [Internet]. 2016 May 25;27(9):1706–1712. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27217541
   PubMed Web of Science ®Google Scholar
• Ottenhof SR, Djajadiningrat RS, de Jong J, et al. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J Urol [Internet]. 2016/10/05 2017;197(3 Part 1):690–697. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27697578
   PubMed Web of Science ®Google Scholar
• Ottenhof SR, Djajadiningrat RS, Thygesen HH, et al. The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma. Front Immunol [Internet]. 2018 Jun 27;9:1253. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29942303
   PubMed Web of Science ®Google Scholar
• Johrens K, Ruschoff J. The challenge to the Pathologist of PD-L1 expression in tumor cells of non-small-cell lung cancer—an overview. Curr Oncol [Internet]. 2021 Dec 24;28(6):5227–5239. Available from. https://www.ncbi.nlm.nih.gov/pubmed/34940076
   PubMed Web of Science ®Google Scholar
• Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol [Internet]. 2018 May 26;13:1302–1311. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29800747
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol [Internet]. 2017 Jun 28;14:655–668. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28653677
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer [Internet]. 2019 Jul 17;7(1):183. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31307554
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (1979) [Internet]. 2015 Mar 15;348: 124–128. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25765070
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell [Internet]. 2020/10/31 2021;39:154–173. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33125859
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res [Internet]. 2020 May 30;30:507–519. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32467593
   PubMed Web of Science ®Google Scholar
• Santaniello A, Napolitano F, Servetto A, et al. Tumour microenvironment and immune evasion in EGFR addicted NSCLC: hurdles and possibilities. Cancers (Basel) [Internet]. 2019 Sep 27. 11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31554160.
   PubMed Web of Science ®Google Scholar
• Ali SM, Pal SK, Wang K, et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncology. 2016;21(1):33–39. doi: 10.1634/theoncologist.2015-0241
   Google Scholar
• McDaniel AS, Hovelson DH, Cani AK, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 2015;75(24):5219–5227. doi: 10.1158/0008-5472.CAN-15-1004
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer [Internet]. 2009 Jul 25;9(8):563–575. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19629071
   PubMed Web of Science ®Google Scholar
• Anderson NM, Simon MC. The tumor microenvironment. Curr Biol [Internet]. 2020 Aug 19;30(16):R921–R925. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32810447
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res [Internet]. 2019 Jul 28;79(18):4557–4566. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31350295
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Phimister EG. Tumor microenvironment, metabolism, and immunotherapy. N Engl J Med [Internet]. 2020 Feb 27;382(9):869–871. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32101671
   PubMed Web of Science ®Google Scholar
• Peranzoni E, Lemoine J, Vimeux L, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc Natl Acad Sci U S A [Internet]. 2018 Apr 11;115(17):E4041–E4050. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29632196
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol [Internet]. 2009 Feb 07;9:162–174. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19197294
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun [Internet]. 2016 Jul 07;7:12150. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27381735
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol [Internet]. 2004 Jan 07;172(2):989–999. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14707072
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res [Internet]. 2006 Jan 21;66(2):1123–1131. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16424049
   PubMed Web of Science ®Google Scholar
• Stiff A, Trikha P, Mundy-Bosse B, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing fc receptor–mediated natural killer cell function. Clin Cancer Res [Internet]. 2018 Jan 25;24(8):1891–1904. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29363526
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol [Internet]. 2005 Aug 02;5:641–654. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16056256
   PubMed Web of Science ®Google Scholar
• Golijanin D, Tan JY, Kazior A, et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res [Internet]. 2004 Feb 12;10(3):1024–1031. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14871981
   PubMed Web of Science ®Google Scholar
• Hennequart M, Pilotte L, Cane S, et al. Constitutive IDO1 expression in Human Tumors Is Driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol Res [Internet]. 2017 Aug 03;5(8):695–709. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28765120
   PubMed Web of Science ®Google Scholar
• McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer [Internet]. 2020 Nov 21;127(6):840–849. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33216356
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A, Tartas S, Mourey L, et al. Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: initial results of PULSE study. J Clin Oncol [Internet]. 2023;41(6_suppl):8. doi: 10.1200/JCO.2023.41.6_suppl.8
   Google Scholar
• de VH, Rafael TS, Gil-Jimenez A, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial. JCO [Internet]. 2023;41(31):4872–4880. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.22.02894
   PubMed Web of Science ®Google Scholar
• Del Muro X G, Cuellar MA, Maroto-Rey P, et al. Phase II study of the efficacy of retifanlimab (rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis. JCO [Internet]. 2023;41(16_suppl):5043. doi: 10.1200/JCO.2023.41.16_suppl.5043
   Google Scholar
• Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer [Internet]. 2020 Mar 20;8(1):e000347. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32188704
   PubMed Web of Science ®Google Scholar
• Apolo AB, Nadal R, Girardi DM, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or Metastatic Urothelial Carcinoma and other genitourinary tumors. J Clin Oncol. 2020;38(31):3672–3684. doi: 10.1200/JCO.20.01652
   PubMed Web of Science ®Google Scholar
• Maluf FC, Trindade K, Preto DDA, et al. A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. J Clin Oncol [Internet]. 2023;41(6_suppl):TPS14–TPS14. doi: 10.1200/JCO.2023.41.6_suppl.TPS14
   Google Scholar
• Yan R, Ma H, Jiang L, et al. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer. BJU Int. 2023;131(2):198–207. doi: 10.1111/bju.15828
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Bigot F, Vansteene D, et al. Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC). J Clin Oncol [Internet]. 2023;41:2597. doi: 10.1200/JCO.2023.41.16_suppl.2597.
   Web of Science ®Google Scholar
• Renninson E, Challapalli A, Foulstone E, et al. A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC trial). J Clin Oncol [Internet]. 2022;40(16_suppl):TPS5094–TPS5094. doi: 10.1200/JCO.2022.40.16_suppl.TPS5094
   Web of Science ®Google Scholar
• Trafalis DT, Alifieris CE, Kalantzis A, et al. Evidence for efficacy of treatment with the anti-PD-1 Mab Nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma. J Immunother [Internet]. 2018 Apr 12;41(6):300–305. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29642086
   PubMed Web of Science ®Google Scholar
• Hahn AW, Chahoud J, Campbell MT, et al. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs [Internet]. 2021 Mar 27;39:1405–1410. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33770291
   PubMed Web of Science ®Google Scholar
• Chahoud J, Th SW, Spiess PE, et al. Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to Pembrolizumab. Front Oncol [Internet]. 2021 Jan 12;10:615298. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33425770
   Web of Science ®Google Scholar
• El Zarif T, Nassar AH, Pond GR, et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst [Internet]. 2023 Aug 11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37563779.
   PubMedGoogle Scholar
• Pouessel D, Beylot-Barry M, Esma SB, et al. 715P nivolumab in pretreated metastatic penile squamous cell carcinoma: results of the penile cohort from the French AcSé prospective program. Ann Oncol [Internet]. 2021;32:S720. doi: 10.1016/j.annonc.2021.08.111
   Web of Science ®Google Scholar
• Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, et al. Chemo-Immunotherapy: a new trend in cancer treatment. Cancers (Basel) [Internet]. 2023 Jun 10;15(11):2912. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37296876
   PubMed Web of Science ®Google Scholar
• TIP (Paclitaxel + Ifosfamide + Cisplatin) combined with nimotuzumab & triprilimab as neoadjuvant treatment in locally advanced penile cancer (NCT04475016). Available from: https://clinicaltrials.gov/study/NCT04475016.
   Google Scholar
• Testing the effectiveness of two immunotherapy drugs (Nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors. Available from: https://www.clinicaltrials.gov/study/NCT03866382cond=PenileCancer&intr=Cabozantinib&rank=2.
   Google Scholar
• Atezolizumab and Bevacizumab in treating patients with rare solid tumors. Available from: https://www.clinicaltrials.gov/study/NCT03074513?cond=NCT03074513&rank=1.
   Google Scholar
• Zhang H, Huang Z, Zou X, et al. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget Internet. 2016 Oct 21;7:82473–82481. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27756883
   PubMedGoogle Scholar
• de Guillebon E, Jimenez M, Mazzarella L, et al. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. ESMO Open [Internet]. 2021 Apr 18;6:100106. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33865192
   PubMed Web of Science ®Google Scholar
• A phase I/II study of combination immunotherapy for advanced cancers including HPV-associated malignancies, small bowel, and colon cancers (NCT04708470). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04708470.
   Google Scholar
• Booty MG, Hlavaty KA, Stockmann A, et al. Microfluidic squeezing enables MHC class I antigen presentation by diverse immune cells to elicit CD8(+) T cell responses with antitumor activity. J Immunol [Internet]. 2022 Jan 30;208(4):929–940. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35091434
   PubMed Web of Science ®Google Scholar
• Study of SQZ-eAPC-HPV in patients with HPV16+ recurrent, locally advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/study/NCT05357898.
   Google Scholar
• Study of SQZ-PBMC-HPV in patients with HPV16+ recurrent, locally advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/study/NCT04084951.
   Google Scholar
• Study of SQZ-AAC-HPV in patients with HPV16+ recurrent, locally advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/study/NCT04892043.
   Google Scholar
• Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch [Internet]. 2018 Nov 25;474(4):449–461. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30470934
   PubMed Web of Science ®Google Scholar
• Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol [Internet]. 2021 Jun 19;12:690499. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34140957
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer Internet. 2020 Aug 06;8(2):e000848. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32753545
   PubMed Web of Science ®Google Scholar
• Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res [Internet]. 2022 Dec 10;29(10):1835–1854. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36485001
   Web of Science ®Google Scholar
• Aydin AM, Hall M, Bunch BL, et al. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol [Internet]. 2021 Feb 27;94:107481. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33636562
   PubMed Web of Science ®Google Scholar
• Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37(15_suppl):2538. [Internet]. doi: 10.1200/JCO.2019.37.15_suppl.2538
   Web of Science ®Google Scholar
• Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med [Internet]. 2021 Feb 10;27:419–425. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33558725
   PubMed Web of Science ®Google Scholar
• Doran SL, Stevanović S, Adhikary S, et al. T-Cell receptor gene therapy for human papillomavirus–associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol. 2019;37(30):2759–2768. doi: 10.1200/JCO.18.02424
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol [Internet]. 2019 Jan 27;94(S1):S3–S9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30680780
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J [Internet]. 2021 Apr 08;11(4):69. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33824268
   PubMed Web of Science ®Google Scholar
• Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther [Internet]. 2021 Jan 27;12:81. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33494834.
   PubMed Web of Science ®Google Scholar
• Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol [Internet]. 2023 Apr 07;14:1113882. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37020537
   PubMed Web of Science ®Google Scholar
• Alemany L, Cubilla A, Halec G, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69(5):953–961. doi: 10.1016/j.eururo.2015.12.007
   PubMed Web of Science ®Google Scholar
• da Rocha WM, da Silva KC, Cavalcanti SMB. The role of oncogenic DNA viruses in penile cancer development. Crit Rev Oncog. 2019;24(4):385–402. doi: 10.1615/CritRevOncog.2020032961
   PubMedGoogle Scholar
• Zhang J, Zhang H, Xiu Y, et al. Prognostic significance of P16INK4a expression in penile squamous cell carcinoma: a meta-analysis with trial sequential analysis. Biomed Res Int. 2018;2018:1–9. doi: 10.1155/2018/8345893
   Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123–F138. doi: 10.1016/j.vaccine.2012.04.108
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Moeller E. 9-valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017;16(11):1119–1139. doi: 10.1080/14760584.2017.1383158
   PubMed Web of Science ®Google Scholar
• Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations. Vaccine. 2017.
   Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated listeria monocytogenes vaccine: a phase I safety study of lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3975–3983. doi: 10.1016/j.vaccine.2009.04.041
   PubMed Web of Science ®Google Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer. JAMA Oncol. 2019;5(1):67. doi: 10.1001/jamaoncol.2018.4051
   PubMed Web of Science ®Google Scholar
• De SL, Rajapakshe K, Rodriguez Canales J, et al. ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10(2):10. doi: 10.1136/jitc-2021-004232
   Web of Science ®Google Scholar
• Borcoman E, Lalanne A, Delord JP, et al. Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. Eur J Cancer. 2023;191:112981. doi: 10.1016/j.ejca.2023.112981
   PubMed Web of Science ®Google Scholar
• Hietanen S, Lain S, Krausz E, et al. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA. 2000;97(15):8501–8506. doi: 10.1073/pnas.97.15.8501
   PubMed Web of Science ®Google Scholar
• Morel A, Baguet A, Perrard J, et al. 5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression. Oncotarget. 2017;8(28):46163–46176. doi: 10.18632/oncotarget.17575
   PubMedGoogle Scholar
• Ajiro M, Sakai H, Onogi H, et al. CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has a therapeutic effect on HPV-induced neoplasia. Clin Cancer Res. 2018;24(18):4518–4528. doi: 10.1158/1078-0432.CCR-17-3119
   PubMed Web of Science ®Google Scholar
• Rescigno P, Matano E, Raimondo L, et al. Combination of docetaxel and cetuximab for penile cancer: A case report and literature review. Anticancer Drugs. 2012;23(5):573–577. doi: 10.1097/CAD.0b013e328350ead7
   PubMed Web of Science ®Google Scholar
• Necchi A, Giannatempo P, Lo Vullo S, et al. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma when surgery and chemotherapy have failed. Clin Genitourin Cancer. 2016;14(3):231–236. doi: 10.1016/j.clgc.2015.08.001
   PubMed Web of Science ®Google Scholar
• An X, Yan R, Guo S, et al. Anti-EGFR antibody plus anti-PD-1 antibody and chemotherapy as a neoadjuvant regimen for patients with locally-advanced penile squamous cell carcinoma: a prospective, single-arm, single-center, phase II clinical trial. J Clin Oncol. 2022;40(16_suppl):5037–5037. doi: 10.1200/JCO.2022.40.16_suppl.5037
   Google Scholar
• Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 2018;121(3):348–356. doi: 10.1111/bju.14013
   PubMed Web of Science ®Google Scholar
• Thomas A, Slade KS, Blaheta RA, et al. Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer. Cancers (Basel). 2022;14(7):14. doi: 10.3390/cancers14071683
   Web of Science ®Google Scholar
• Thomas A, Reetz S, Stenzel P, et al. Assessment of pi3k/mtor/akt pathway elements to serve as biomarkers and therapeutic targets in penile cancer. Cancers (Basel). 2021;13(10):2323. doi: 10.3390/cancers13102323
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078. doi: 10.1038/nature08467
   PubMed Web of Science ®Google Scholar
• Harold J, Bellone S, Manavella DD, et al. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecol Oncol. 2023;168:157–165. doi: 10.1016/j.ygyno.2022.11.014
   PubMed Web of Science ®Google Scholar
• Leibrandt R, Frankel PH, Beumer JH, et al. A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma. J Clin Oncol. 2022;40(16_suppl):TPS3174–TPS3174. doi: 10.1200/JCO.2022.40.16_suppl.TPS3174
   Web of Science ®Google Scholar
• Pusch F, García HD, Xu R, et al. Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models. bioRxiv. 2022.
   Google Scholar
• Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy. Eur J Pharmacol. 2021;911:174516. doi: 10.1016/j.ejphar.2021.174516
   PubMed Web of Science ®Google Scholar
• Grass GD, Chahoud J, Lopez A, et al. An analysis of nectin-4 (PVRL4) in penile squamous cell carcinoma. Eur Urol Open Sci. 2023;49:1–5. doi: 10.1016/j.euros.2022.12.008
   PubMedGoogle Scholar
• Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in Previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–1135. doi: 10.1056/NEJMoa2035807
   PubMed Web of Science ®Google Scholar
• Tan X, Wang Y, Wu Z, et al. The role of her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy. Eur J Cancer. 2023;194:113360. doi: 10.1016/j.ejca.2023.113360
   PubMed Web of Science ®Google Scholar
• Tekin B, Cheville JC, Herrera Hernandez L, et al. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. Hum Pathol. 2023;142:42–50. doi: 10.1016/j.humpath.2023.10.003
   PubMed Web of Science ®Google Scholar
• Busso-Lopes AF, Marchi FA, Kuasne H, et al. Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev Res. 2015;8(2):149–156. doi: 10.1158/1940-6207.CAPR-14-0284
   PubMed Web of Science ®Google Scholar
• Chaux A, Munari E, Katz B, et al. The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. Hum Pathol. 2013;44(12):2690–2695. doi: 10.1016/j.humpath.2013.07.012
   PubMed Web of Science ®Google Scholar
• Lavens N, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. Current Oncol. 2010;17(1):4–6. doi: 10.3747/co.v17i1.471
   PubMed Web of Science ®Google Scholar
• Wei H, Yu X. Functions of PARylation in DNA damage repair pathways. Genomics Proteomics Bioinf [Internet]. 2016 Jun 01;14(3):131–139. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27240471
   PubMed Web of Science ®Google Scholar
• Xue C, Xu Y, Ye W, et al. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol [Internet]. 2020 Jan 29;157(1):222–233. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31987601
   PubMed Web of Science ®Google Scholar
• Meng J, Peng J, Feng J, et al. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. J Transl Med [Internet]. 2021 Oct 09;19:415. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34620163
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng K, Xiong H, et al. PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer. Front Immunol [Internet]. 2022 Jan 04;12:762989. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34975854
   Web of Science ®Google Scholar
• Zhang N, Gao Y, Huang Z, et al. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. Cancer Lett [Internet]. 2022 Aug 05;545:215852. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35926817.
   PubMed Web of Science ®Google Scholar
• Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-Dependent antitumor immunity in Brca1-Deficient ovarian cancer. Cell Rep [Internet]. 2018 Dec 13;25(11):2972–2980 e5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30540933
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA -Mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. doi: 10.1056/NEJMoa1813904
   PubMed Web of Science ®Google Scholar
• Necchi A, Spiess PE, Costa de Padua T, et al. Genomic profiles and clinical outcomes of penile squamous cell carcinoma with elevated tumor mutational burden. JAMA Netw Open [Internet]. 2023;6(12):e2348002. doi: 10.1001/jamanetworkopen.2023.48002
   PubMed Web of Science ®Google Scholar
• Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor–positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–2070. doi: 10.1056/NEJMoa2214131
   PubMed Web of Science ®Google Scholar
• Lee JH, Paull TT. Cellular functions of the protein kinase ATM and their relevance to human disease. Nat Rev Mol Cell Biol. 2021;22(12):796–814. doi: 10.1038/s41580-021-00394-2
   PubMed Web of Science ®Google Scholar
• Sartori G, Tarantelli C, Spriano F, et al. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. Br J Haematol. 2023;204(1): 191–205.
   PubMed Web of Science ®Google Scholar
• Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93–103. doi: 10.1038/s41585-020-00394-5
   PubMed Web of Science ®Google Scholar
• Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929–1935. doi: 10.1007/s40265-021-01614-x
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3–4):84–105. doi: 10.18632/genesandcancer.40
   PubMedGoogle Scholar
• Kim YE, Hipp MS, Bracher A, et al. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem [Internet]. 2013 Jun 12;82(1):323–355. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23746257
   PubMedGoogle Scholar
• Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol [Internet]. 2013 Sep 13;14:630–642. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24026055
   PubMed Web of Science ®Google Scholar
• Shrestha L, Bolaender A, Patel HJ, et al. Heat shock protein (HSP) drug discovery and development: targeting heat shock proteins in disease. Curr Top Med Chem [Internet]. 2016 Apr 14;16(25):2753–2764. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27072696
   PubMed Web of Science ®Google Scholar
• Falchook GS, Bendell JC, Ulahannan SV, et al. Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: phase I and expansion cohort results. J Clin Oncol [Internet]. 2020;38(15_suppl):3515. doi: 10.1200/JCO.2020.38.15_suppl.3515
   Web of Science ®Google Scholar
• Shum E, Reilley M, Najjar Y, et al. 523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer [Internet]. 2021;9(Suppl 2):A553–A553. doi: 10.1136/jitc-2021-SITC2021.523
   Google Scholar
• Witty K, Branney P, Evans J, et al. The impact of surgical treatment for penile cancer – patients’ perspectives. Eur J Oncol Nurs [Internet]. 2013 Jul 31;17(5):661–667. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23896180
   PubMed Web of Science ®Google Scholar
• Sosnowski R, Kulpa M, Kosowicz M, et al. Quality of life in penile carcinoma patients - post-total penectomy. Cent European J Urol [Internet]. 2016 Aug 24;69(2):204–211. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27551559
   PubMed Web of Science ®Google Scholar
• Bandini M, Ahmed M, Basile G, et al. A global approach to improving penile cancer care. Nat Rev Urol [Internet]. 2021/12/24 2022;19:231–239. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34937881
   PubMed Web of Science ®Google Scholar